Atara Biotherapeutics Transfers Tabelecleucel BLA to Pierre Fabre for EBV+ PTLD Treatment

Atara Biotherapeutics: A Shift in Focus for an Innovative Therapy

Atara Biotherapeutics Inc. transfers the Biologics License Application (BLA) for tabelecleucel to Pierre Fabre Pharmaceuticals Inc. (PFP), marking a pivotal moment in the development of this groundbreaking allogeneic T-cell therapy. Tabelecleucel targets Epstein-Barr virus-positive post-transplant lymphoproliferative disorder (EBV+ PTLD), a rare and often lethal blood malignancy that affects patients following hematopoietic or solid organ transplants. The therapy is currently under U.S. Food and Drug Administration (FDA) Priority Review, with a Prescription Drug User Fee Act (PDUFA) target action date set for January 10, 2026. The transfer of the BLA signifies PFP's assumption of full responsibility for the therapy's clinical development and commercial activities worldwide, highlighting a crucial step toward making this innovative treatment available to patients in need.

The urgency surrounding tabelecleucel is underscored by the dire prognosis faced by EBV+ PTLD patients, who often have a life expectancy of mere weeks to months following the failure of initial treatments. Tabelecleucel aims to change this narrative by offering an off-the-shelf T-cell immunotherapy designed to specifically target and eliminate EBV-infected cells. The therapy is backed by clinical data from more than 430 patients, including promising results from the ongoing pivotal ALLELE study. Adriana Herrera, CEO of PFP, remarks on the significance of this transition, emphasizing the collaboration with the FDA as a critical factor in bringing this much-needed therapy to market and ultimately improving patient outcomes.

As PFP takes the reins, the company commits to ensuring that the therapy undergoes a rigorous review process. The resubmission of the BLA on July 11, 2025, followed by its acceptance for review on July 23, 2025, demonstrates the ongoing momentum behind tabelecleucel. This collaboration between Atara and PFP reflects a broader shift in the biopharmaceutical industry, where partnerships play a vital role in advancing innovative therapies through the regulatory landscape. The hope remains that tabelecleucel will provide a viable treatment option for patients suffering from EBV+ PTLD, ultimately contributing to the evolution of cancer therapies.

In related news, the focus on allogeneic cell therapies continues to grow, as companies like Atara Biotherapeutics and PFP invest in developing treatments for rare and challenging conditions. The progress of tabelecleucel exemplifies the potential for transformational therapies to emerge from collaborative efforts in the biopharmaceutical sector. As the industry moves forward, the emphasis on innovative solutions for unmet medical needs remains a priority for companies dedicated to improving patient care.